Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical Therapy

Background and objective: Urine alkalinization, the mainstay of uric acid (UA) stone dissolution medical therapy, relies on old in vitro studies and expert opinions. Moreover, the effects of lowering urine UA concentration in patients without hyperuricosuria have rarely been investigated. We revisit...

Full description

Saved in:
Bibliographic Details
Main Authors: Paz Lotan, Michael Mastai, Yitzhak Mastai, Sapir Shekef Aloni, Itay Sagy, Bezalel Sivan, Abd E. Darawsha, David Lifshitz
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:European Urology Open Science
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168325001090
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849691736332304384
author Paz Lotan
Michael Mastai
Yitzhak Mastai
Sapir Shekef Aloni
Itay Sagy
Bezalel Sivan
Abd E. Darawsha
David Lifshitz
author_facet Paz Lotan
Michael Mastai
Yitzhak Mastai
Sapir Shekef Aloni
Itay Sagy
Bezalel Sivan
Abd E. Darawsha
David Lifshitz
author_sort Paz Lotan
collection DOAJ
description Background and objective: Urine alkalinization, the mainstay of uric acid (UA) stone dissolution medical therapy, relies on old in vitro studies and expert opinions. Moreover, the effects of lowering urine UA concentration in patients without hyperuricosuria have rarely been investigated. We revisited the UA dissolution kinetics to determine the optimal alkalinization target and evaluate the effect of reducing urine UA saturation below normal levels. Methods: Ultraviolet-visible spectrophotometry was employed to analyze the dissolution kinetics of intact and grounded stones in artificial urine solution at various pH levels and UA concentrations. Crystal structures of precipitates were examined by X-ray diffraction. Key findings and limitations: The average dissolution rate increased fourfold when the pH rose from 6–6.5 to 6.5–7 and ninefold when it reached 7–7.2, with the optimal level being at 7.2. At pH 7.4, the rate dropped significantly, and hydroxyapatite crystals precipitated. Grounded stones dissolved 10-fold faster than intact stones at each pH level. Lowering of the urine UA concentration enhanced the dissolution rate only at pH >6.5 and after reducing the concentrations by 55% of the normal level. The artificial urine, buffering solution, and model could only partially mimic the in vivo urine environment. Conclusions and clinical implications: The in vitro study of UA dissolution kinetics offers valuable insights for improving medical therapy in patients with UA nephrolithiasis. Our study confirms alkalinization as the key factor for dissolution and supports expert recommendations. Specifically, by maintaining urine pH >6.5, preferably 7–7.2, and increasing stone surface area, dissolution can be optimized. Reduction of UA concentrations in patients without hyperuricosuria enhances dissolution only after sufficient alkalinization. Patient summary: In this report, we used contemporary laboratory methods to refine the optimal pH target of urine alkalinization, the mainstay medical therapy for uric acid stone dissolution. We found the dissolution rate to increase mainly at pH levels above 6.5, with the optimal pH being 7.2. Additionally, increasing the stone surface area by fragmentation increased the dissolution further, implicating a potential second-line option when initial treatment is unsuccessful. Finally, we confirmed the expert-based recommendation on the lack of effectiveness of allopurinol treatment without adequate alkalinization in patients who have normal uric acid urinary excretion.
format Article
id doaj-art-7a2c0925009346668e5d276ae438f424
institution DOAJ
issn 2666-1683
language English
publishDate 2025-06-01
publisher Elsevier
record_format Article
series European Urology Open Science
spelling doaj-art-7a2c0925009346668e5d276ae438f4242025-08-20T03:20:56ZengElsevierEuropean Urology Open Science2666-16832025-06-0176384410.1016/j.euros.2025.04.003Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical TherapyPaz Lotan0Michael Mastai1Yitzhak Mastai2Sapir Shekef Aloni3Itay Sagy4Bezalel Sivan5Abd E. Darawsha6David Lifshitz7Department of Urology, University of Wisconsin, School of Medicine and Public Health, Madison, WI, USA; Department of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Corresponding author. Department of Urology, University of Wisconsin, School of Medicine and Public Health, 1685 Highland Avenue, Madison, WI 53705, USA. Tel. +1 716 249 9629; Fax: +1 608 262 6453.Adelson School of Medicine, Ariel University, Ariel, IsraelDepartment of Chemistry and Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, Ramat Gan, IsraelDepartment of Chemistry and Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, Ramat Gan, IsraelDepartment of Urology, Wolfson Medical Center, Holon, IsraelDepartment of Urology, Chaim Sheba Medical Center at Tel Hashomer, Ramat Gan, IsraelDepartment of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Urology, Rabin Medical Center, Petach Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelBackground and objective: Urine alkalinization, the mainstay of uric acid (UA) stone dissolution medical therapy, relies on old in vitro studies and expert opinions. Moreover, the effects of lowering urine UA concentration in patients without hyperuricosuria have rarely been investigated. We revisited the UA dissolution kinetics to determine the optimal alkalinization target and evaluate the effect of reducing urine UA saturation below normal levels. Methods: Ultraviolet-visible spectrophotometry was employed to analyze the dissolution kinetics of intact and grounded stones in artificial urine solution at various pH levels and UA concentrations. Crystal structures of precipitates were examined by X-ray diffraction. Key findings and limitations: The average dissolution rate increased fourfold when the pH rose from 6–6.5 to 6.5–7 and ninefold when it reached 7–7.2, with the optimal level being at 7.2. At pH 7.4, the rate dropped significantly, and hydroxyapatite crystals precipitated. Grounded stones dissolved 10-fold faster than intact stones at each pH level. Lowering of the urine UA concentration enhanced the dissolution rate only at pH >6.5 and after reducing the concentrations by 55% of the normal level. The artificial urine, buffering solution, and model could only partially mimic the in vivo urine environment. Conclusions and clinical implications: The in vitro study of UA dissolution kinetics offers valuable insights for improving medical therapy in patients with UA nephrolithiasis. Our study confirms alkalinization as the key factor for dissolution and supports expert recommendations. Specifically, by maintaining urine pH >6.5, preferably 7–7.2, and increasing stone surface area, dissolution can be optimized. Reduction of UA concentrations in patients without hyperuricosuria enhances dissolution only after sufficient alkalinization. Patient summary: In this report, we used contemporary laboratory methods to refine the optimal pH target of urine alkalinization, the mainstay medical therapy for uric acid stone dissolution. We found the dissolution rate to increase mainly at pH levels above 6.5, with the optimal pH being 7.2. Additionally, increasing the stone surface area by fragmentation increased the dissolution further, implicating a potential second-line option when initial treatment is unsuccessful. Finally, we confirmed the expert-based recommendation on the lack of effectiveness of allopurinol treatment without adequate alkalinization in patients who have normal uric acid urinary excretion.http://www.sciencedirect.com/science/article/pii/S2666168325001090Uric acidNephrolithiasisKineticsChemolysisStone dissolutionMedical therapy
spellingShingle Paz Lotan
Michael Mastai
Yitzhak Mastai
Sapir Shekef Aloni
Itay Sagy
Bezalel Sivan
Abd E. Darawsha
David Lifshitz
Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical Therapy
European Urology Open Science
Uric acid
Nephrolithiasis
Kinetics
Chemolysis
Stone dissolution
Medical therapy
title Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical Therapy
title_full Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical Therapy
title_fullStr Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical Therapy
title_full_unstemmed Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical Therapy
title_short Revisiting Uric Acid Stone Dissolution Kinetics: Insights for Optimizing Medical Therapy
title_sort revisiting uric acid stone dissolution kinetics insights for optimizing medical therapy
topic Uric acid
Nephrolithiasis
Kinetics
Chemolysis
Stone dissolution
Medical therapy
url http://www.sciencedirect.com/science/article/pii/S2666168325001090
work_keys_str_mv AT pazlotan revisitinguricacidstonedissolutionkineticsinsightsforoptimizingmedicaltherapy
AT michaelmastai revisitinguricacidstonedissolutionkineticsinsightsforoptimizingmedicaltherapy
AT yitzhakmastai revisitinguricacidstonedissolutionkineticsinsightsforoptimizingmedicaltherapy
AT sapirshekefaloni revisitinguricacidstonedissolutionkineticsinsightsforoptimizingmedicaltherapy
AT itaysagy revisitinguricacidstonedissolutionkineticsinsightsforoptimizingmedicaltherapy
AT bezalelsivan revisitinguricacidstonedissolutionkineticsinsightsforoptimizingmedicaltherapy
AT abdedarawsha revisitinguricacidstonedissolutionkineticsinsightsforoptimizingmedicaltherapy
AT davidlifshitz revisitinguricacidstonedissolutionkineticsinsightsforoptimizingmedicaltherapy